Akums Q2 FY27: Revenue Up 31.9% to ₹1,342 Cr, PAT Soars 168%
Akums reported Q2 FY27 results with revenue up 31.9% to ₹1,342 crore and PAT soaring 168% to ₹115 crore. EBITDA grew 106% to ₹195 crore. The company also acquired Oriflame India's manufacturing business for ₹56 crore to enter colour cosmetics.
The significant growth in key financial metrics like revenue and PAT, coupled with a strategic acquisition that diversifies the company's business, will likely have a high impact on investor sentiment and the company's market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, indicating a positive financial performance. The strategic acquisition also adds to the positive outlook.
Akums Drugs & Pharmaceuticals Ltd. announced its consolidated financial results for the quarter ended September 30, 2026, reporting significant year-on-year growth across key financial metrics.
For Q2 FY27, revenue surged by 31.9% to ₹1,342 crore from ₹1,018 crore in Q2 FY26. EBITDA saw a substantial increase of 106%, reaching ₹195 crore compared to ₹94 crore in the prior-year period, with the EBITDA margin improving to 14.5% from 9.3%. Profit After Tax (PAT) grew by an impressive 168% to ₹115 crore from ₹43 crore, and PAT margin improved to 8.4% from 4.1%.
The company also demonstrated strong performance in the first half of FY27 (H1 FY27). Revenue stood at ₹2,509 crore, a 22.9% increase from H1 FY26's ₹2,042 crore. EBITDA for H1 FY27 rose by 65.3% to ₹369 crore, and PAT doubled to ₹216 crore from ₹107 crore in the corresponding period last year.
The Contract Development and Manufacturing Organisation (CDMO) business remained a key growth driver, with Q2 FY27 revenue at ₹1,115 crore, up 38.6% year-on-year. CDMO EBITDA increased by 99.6% to ₹168 crore.
In a strategic move to diversify, Akums, through its subsidiary Pure & Cure Healthcare Private Limited, acquired Oriflame India's manufacturing business for ₹56 crore. This acquisition includes two manufacturing facilities and a warehouse, marking Akums' entry into colour cosmetics manufacturing and expanding its capabilities in skincare and wellness products.
Commenting on the results, Managing Directors Mr. Sanjeev Jain and Mr. Sandeep Jain highlighted the company's commitment to strengthening its CDMO position, investing in manufacturing infrastructure, and expanding capabilities for global markets, with over 30 products in the pipeline for European markets.
What to do with a filing like this
Akums Drugs and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Akums Drugs and Pharmaceuticals Limited. Read the original for the full detail.